JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells

British Journal of Haematology

Volumn 135, Issue 1, 2006, Pages 26-32

  Shi, Xinzhe ^a   Franko, Bevin ^a   Frantz, Christine ^a   Amin, Hesham M ^b   Lai, Raymond ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; Janus kinase 3; JSI 124; Nucleophosmin anaplastic lymphoma kinase; Signal transducer and activator of transcription 3

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CASPASE 3; CUCURBITACIN 1; CYCLIN D3; JANUS KINASE 1; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; NUCLEOPHOSMIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL TYPE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; JANUS KINASE 3; LYMPHOMA, LARGE-CELL; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR CELLS, CULTURED;

EID: 33748341084     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06259.x     Document Type: Article

References (23)

1. Amin, H.M., Medeiros, L.J., Ma, Y., Feretzaki, M., Das, P., Leventaki, V., Rassidakis, G.Z., O'Connor, S.L., McDonnell, T.J. & Lai, R. (2003) Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene, 22, 5399-5407.
2. Amin, H.M., McDonnell, T.J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., Leventaki, V., Das, P., Rassidakis, G.Z., Cutler, C., Medeiros, L.J. & Lai, R. (2004) Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene, 23, 5426-5434.
3. Bai, R.Y., Dieter, P., Peschel, C., Morris, S.W. & Duyster, J. (1998) Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Molecular and Cellular Biology, 18, 6951-6961.
4. Blaskovich, M.A., Sun, J., Cantor, A., Turkson, J., Jove, R. & Sebti, S.M. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research, 63, 1270-1279.
5. Bonvini, P., Gastaldi, T., Falini, B. & Rosolen, A. (2002) Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Research, 62, 1559-1566.
6. Bowman, T., Yu, H., Sebti, S., Dalton, W. & Jove, R. (1999) Signal transducers and activators of transcription: novel targets for anticancer therapeutics. Cancer Control, 6, 427-435.
7. Bowman, T., Garcia, R., Turkson, J. & Jove, R. (2000) STATs in oncogenesis. Oncogene, 19, 2474-2488.
8. Bromberg, J. (2002) Stat proteins and oncogenesis. The Journal of Clinical Investigation, 109, 1139-1142.
9. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C. & Darnell, J.E. (1999) Stat3 as an oncogene. Cell, 98, 295-303.
10. Chiarle, R., Gong, J.Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W.J., Dhall, G., Howes, J., Piva, R. & Inghirami, G. (2003) NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 101, 1919-1927.
11. Chiarle, R., Simmons, W.J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J.G., Levy, D.E. & Inghirami, G. (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine, 11, 623-629.
12. Cussac, D., Greenland, C., Roche, S., Bai, R.Y., Duyster, J., Morris, S.W., Delsol, G., Allouche, M. & Payrastre, B. (2004) Nucleophosmin- anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood, 103, 1464-1471.
13. Delsol, G., Ralfkiaer, E., Stein, H., Wright, D. & Jaffe, E. (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization (WHO) Classification of Tumors, pp. 230-235. IARC Press. Lyon.
14. Duyster, J., Bai, R.Y. & Morris, S.W. (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene, 20, 5623-5637.
15. Khoury, J.D., Medeiros, L.J., Rassidakis, G.Z., Yared, M.A., Tsioli, P., Leventaki, V., Schmitt-Graeff, A., Herling, M., Amin, H.M. & Lai, R. (2003) Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clinical Cancer Research, 9, 3692-3699.
16. Kuefer, M.U., Look, A.T., Pulford, K., Behm, F.G., Pattengale, P.K., Mason, D.Y. & Morris, S.W. (1997) Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood, 90, 2901-2910.
17. Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, D.L. & Look, A.T. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 263, 1281-1284.
18. Slupianek, A., Nieborowska-Skorska, M., Hoser, G., Morrione, A., Majewski, M., Xue, L., Morris, S.W., Wasik, M.A. & Skorski, T. (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Research, 61, 2194-2199.
19. Turkson, J. & Jove, R. (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19, 6613-6626.
20. Turner, S.D. & Alexander, D.R. (2005) What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia, 19, 1128-1134.
21. Yu, C.L. & Burakoff, S.J. (1997) Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. The Journal of Biological Chemistry, 272, 14017-14020.
22. Zamo, A., Chiarle, R., Piva, R., Howes, J., Fan, Y., Chilosi, M., Levy, D.E. & Inghirami, G. (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 21, 1038-1047.
23. Zhang, Q., Raghunath, P.N., Xue, L., Majewski, M., Carpentieri, D.F., Odum, N., Morris, S., Skorski, T. & Wasik, M.A. (2002) Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. The Journal of Immunology, 168, 466-474.